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ABSTRACT 
Parkinson's disease is the slow-progressing chronic neurodegenerative disease. It caused by the 
progressive destruction and death of neurons that produce the neurotransmitter dopamine, 
primarily in the substantia nigra and also in other parts of the Central nervous system. Insufficient 
production of dopamine leads to the activating influence of the basal ganglia to the cerebral 
cortex. Guiding symptoms are muscle rigidity, hypokinesia, tremor, postural instability. Modern 
medicine has not yet found methods of curing disease, however, the existing methods of 
conservative and surgical treatment significantly improve the patient’s quality of life and slow the 
progression of the disease. There is an assumption of the key role of glutamate receptors 
excessive activation in the pathogenesis of Parkinson's disease. It can be expected that glutamate 
receptors may be a new therapeutic target in the treatment of this pathology. The study of 
glutamate receptors blockers is an important task in the search for new pharmacological agents in 
the treatment of Parkinson's disease. Experiments on animal models suggest the change in the 
activity of these receptors can facilitate the primary motor symptoms of Parkinson's disease and 
also side effects caused by the levodopa replacement therapy. AMPA- NMDA receptors 
antagonists have shown the ability to reverse motor symptoms and levodopa-induced dyskinesia 
in preclinical models of Parkinson's disease. Metabotropic glutamate receptors antagonists are 
even more promising in the treatment of Parkinson's disease due to more "accurate" work in the 
synapse. These drugs also reduce motor deficits, as well as protecting the patient from 
neurodegeneration. Thus glutamate receptors are a promising target for the development of new 
pharmacological treatments of Parkinson's disease.  
Key words: Parkinson's disease, glutamate receptors, basal ganglia, NMDA receptors, AMPA 
receptors, metabotropic glutamate receptors, levodopa-induced dyskinesia. 
INTRODUCTION 
First the Parkinson's disease (PD) was described 
by London physician James Parkinson in 1817 in “An 
Essay on the shaking palsy”, therefore French 
neurologist Jean Charcot proposed to name the disease 
after Parkinson [1]. This disease is a slow-progressing 
chronic neurodegenerative disease, which affects about 
3% of the population aged 55 years and older 
worldwide. Recently, in connection with the increase in 
life expectancy and improvement of diagnostic 
capabilities of medicine, there is PD some incidence 
rate. Guiding symptoms of PD are muscular rigidity, 
hypokinesia, tremor, postural instability, and sleep 
disturbance and cognitive defects [2]. Movement 
disorders, which are major clinical implications, are 
caused by a sharp fall in synthesis of dopamine in the 
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substantia nigra and striatum. Normally the amount of 
dopamine in these formations is hundreds times higher 
than the concentration in other brain structures, 
suggesting an important role of dopamine transmission 
in the activities extra pyramidal system. Loss of 
dopamine innervation of the neostriatum plays a crucial 
role in the control of motor activity [3]. Today 
dopamine replacement therapy is background at the 
unwrapped phase of PD. Because dopamine does not 
pass through the blood-brain barrier (BBB), its 
predecessor levodopa was synthesized. Levodopa 
passes through the BBB and metabolized in the brain 
under the action of dopamine decarboxylase to 
dopamine. Therapy of early disease begins with 
administration of dopamine receptor agonists [4]. 
Dopamine receptor agonists due to its chemical 
properties directly stimulate dopamine receptors, 
reproducing the effect of dopamine. Historically, they 
were first administrated to patients with PD as add-on 
therapy to levodopa, but later it was found that in the 
early disease of dopamine receptor agonists have 
comparable effect with levodopa. In most patients these 
drugs provide of motor symptomatic relief for several 
years. However, chronic exposure of these drugs leads 
to the emergence of motor fluctuations and drug-
induced dyskinesia that militate against their long-term 
effectiveness [4, 5]. Adjuvant treatment to 
monoaminooxidase inhibitors, anticholinergic drug and 
COMT-inhibitors limited improves the effectiveness 
and acceptability of the treatment to levodopa. 
However, more effective therapy for unwrapped 
phase of motor symptoms of PD has not yet been 
found [4]. Besides, used at present pharmacological 
agents (mainly drugs containing levodopa) do not 
slow down the continued degeneration of 
dopaminergic neurons, which functional activity 
causes the conversion of levodopa into dopamine by 
action of dopamine decarboxylase and requires a 
gradual increase of the dose level to achieve the 
effect. This ultimately leads to acerbation of PD. 
Sameness of therapeutic agents for the treatment of 
PD largely associated with a deficit in knowledge on 
the cellular processes underlying the degeneration of 
dopaminergic neurons of the substantia nigra. The 
limitation of the pharmacological treatment of PD 
insists on the importance of non-dopaminergic 
therapeutic strategies for the treatment of the disease 
symptoms. Progress in the understanding of the 
anatomy and function of basal ganglia has given the 
opportunity to develop new strategies for treatment and 
slowing the progression of PD [3].  So the glutamate 
receptors have been proposed as promising therapeutic 
target for treatment of PD, since they transmit fast 
excitatory signals in fiber connection. Pharmacological 
manipulation of these receptors can change both normal 
and pathological neurotransmission that is observed in 
parkinsonian brain.  
PATHOPHYSIOLOGIC MECHANISMS 
OF PARKINSON'S DISEASE 
Clinical symptoms of PD (akinesia, rigidity, 
tremor) are caused by a sharp fall in synthesis of 
dopamine in the substantia nigra and striatum. The 
synthesis of dopamine takes place in the nerve cell 
bodies of the nigrostriatal system. Here the mediator is 
formed in the form of small vesicles, which are 
transported by the axonal transport to the presynaptic 
membane. Under the influence of nervous impulse 
dopamine release in the synaptic cleft and impacting on 
the receptors of the postsynaptic membrane with an 
effect of its depolarization. It is assumed that about 80% 
of dopamine is absorbed in the presynaptic terminals on 
reuptake mechanism or are inactivated by COMT or 
monoamine oxidase type B (MAO-B). Such disorders 
of intrinsic cellular metabolism as a violation of 
mitochondrial respiration and energy failure of the 
neuron, the strengthening of free-radical oxidation with 
the formation of aggressive peroxides, excessive 
accumulation of free ions of Ca
2+
, increased activity of 
glutamate excitotoxin are a key player in the factors 
contributing to degeneration and apoptosis of neurons.  
L-glutamate is the major excitatory 
neurotransmitter in the brain of animals. Glutamate is 
found in all departments of a CNS, as it is not only a 
neurotransmitter but also a precursor of other amino 
acids. Bodies of glutamatergic neurons located in the 
cerebral cortex, olfactory bulbs, hippocampus, 
substantia nigra, cerebellum, retina. Glutamatergic 
synapses located in the tonsil of cerebellum, the 
striatum, granule neurons of the cerebellum. 
Glutamate is dispensable amino acid, it doesn’t pass 
through the BBB, does not arrive to the brain through 
the blood. The synthesis is carried out in the brain, 
mainly intraneural. In addition to the main role of the 
excitatory neurotransmitter, glutamate can cause 
damage and death of dopaminergic neurons. This 
action of glutamate on neurons is designated by the 
term excitotoxicity [6].  
Glutamate-mediated activity detected in almost 
all brain structures. The greatest number of binding 
sites is located in the cerebral cortex, hippocampus, 
striatum, mesencephalon and hypothalamus. 
Glutamate receptors are divided into ionotropic and 
metabotropic. There are several subtypes of 
glutamate receptors. Modern classification of 
ionotropic receptors based on their different 
sensitivity to the action of NMDA, AMPA, kainic 
acid and quisqualic acid. There are two groups of 
receptors: NMDA and non-NMDA (it is divided into 
AMPA and kainate).  
Glutamate excitotoxicity is mediated by NMDA 
receptors. After glutamate occupancies these 
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receptors transport channels of neural membranes 
open and the access of glutamate to the neuron 
enables. Extensive binding of glutamate by NMDA 
receptors leads to increasing of current Ca
2+
 into the 
neuron through the channels of NMDA receptors. 
Due to the fact that the increasing of current Ca
2+
 is 
one of the leading mechanisms of the neuron death, it 
can be assumed that the mechanism of glutamate 
excitotoxicity in PD is associated with massive 
entrance of Ca
2+
 in dopaminergic neurons of the 
substantia nigra [7]. There is a hypothesis about the 
integral role of hyperactivation of the glutamatergic 
structures of Luys body in the pathogenesis of PD.  
Luys body performs the relateral tell of corticonigral 
glutamatergic influences [8]. The hypothesis 
postulates the importance of glutamate damage 
neurons of substantia nigra, starting from the pre-
existing disease.  
NMDA receptors consist of five subunits that 
are complexes of glycoprotein and lipids. The 
NMDA receptor is a receptor-ionophore complex, 
which includes 1) specific binding site of the 
mediator (L-glutamic acid); 2) regulatory or 
coactivativation specific binding site of glycine; 
3) allosteric modulatory sites located on the
membrane (polyamine) and ion channel 
(phencyclidine binding sites, divalent cation and 
voltage-gated Mg-binding site). Mg
2+
 ions selectively 
block the activity of receptors at high hyper 
polarization or depolarization. Glycine enhances the 
responses of NMDA receptor by increasing the 
opening frequency of the channel. In the absence of 
the glycine receptor is not activated by L-glutamate 
[6, 9]. It is known that NMDA receptors play an 
important role in learning and memory. Activation of 
glutamate receptors is considered a universal 
pathochemical process, causing damage to nerve 
cells in a variety of pathological states [4]. The 
neurotransmitter role of the glutamic acid lies in the 
ability to cause membrane depolarization of the 
neuron and therefore increase the conductivity of Ca
2+
 ions. Mediator function is in close connection with
the exchange of Ca
2+
 that gives the opportunity to 
talk about the glutamate-calcium cascade. The 
glutamate action is manifested through the operation 
with specific neuroreceptors with protein structure 
and related in nature to cellular glycoproteins. 
Adverse of biochemical processes, observed in PD, 
triggers the glutamate-calcium cascade, leading to 
different changes in cellular metabolism caused 
primarily by activation of the membrane 
permeability and the m7ovement of Ca
2+
 inside the 
cell [9]. This phenomenon contributes to the adverse 
of fundamental cellular processes, uncoupling 
of  oxidative phosphorylation, free  radical formation, 
which in turn leads to increasing lipid 
peroxygenation, apoptosis and neuron death. 
BASAL GANGLIA AND PARKINSON'S 
DISEASE 
All the movements performed by man, are 
controlled by the Central CNS, which includes the brain 
and spinal cord. It is very difficult organized system that 
meets virtually all that happens in the body. The role of 
higher nervous activity belongs to the cerebral cortex. 
Once man only to think about some intentional action, 
the cortex is already leading to readiness all the systems 
that are responsible for this action. One of such system 
is the so-called basal ganglia. The basal ganglia are an 
auxiliary motor system. It does not work independently, 
but in the close association with the cerebral cortex. The 
basal ganglia are involved in performing complex 
movements such as writing, drawing, walking, kicking 
the ball into the goal, lace shoes etc. It is responsible for 
driving speed and for the accuracy and quality of 
movements. Such movements are self-produced, so 
initially arising in the cerebral cortex. Hence, 
information on these movements comes into the basal 
ganglia that determine which muscles will be 
participate in them and how each of the muscles must 
be stressed that the movements were as precise and 
focused. 
The basal ganglia consist of the nucleus caudatus 
and neostriatum, globus pallidus internus and externus, 
pars reticulate and pars compacta of substantia nigra 
and the Luys body. Neostriatum is the main part of the 
basal ganglia, which receives information from the 
cortex in accordance with somatotopic organization, 
and intralaminar nucleus of thalamus. The information 
comes from the basal ganglia, mainly through the 
globus pallidus internus and pars reticulate of the 
substantia nigra, passes through the thalamus (ventral 
intermediate nucleus  and nucleus ventralis anterior), 
which are projected to the premotor cortex, the 
supplementary motor area and prefrontal cortex. The 
basal ganglia form several neuronal connections. There 
is striato-nigro-striatal connection, the end body of 
which is dopaminergic. This path degenerates in PD 
with the formation of cell inclusions Lewy bodies. 
There is also the connection between globus pallidus 
externus and Luys body, which is then projected in the 
globus pallidus internus and pars reticulate of the 
substantia nigra. This path is by nature excitatory and 
monitors the level of pulsation of the inhibitory neurons 
of the basal ganglia of thalamic areas. Despite the fact 
that the structure of the basal ganglia there is some 
degree of divergence and convergence relations, their 
projections form a parallel path, which in its most 
simplified form are classified on the motor way through 
the putamen, and non-motor way through the caudate 
nucleus. 
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The basal ganglia transmit their impulses with 
the help of special chemical compounds, called 
neurotransmitters. Their number and mechanism of 
action (exciting or inhibiting) determine how muscles 
will work. Dopamine is main inhibitory 
neurotransmitter which is secreted in the caudate 
nucleus and the putamen, therefore the destruction of 
dopaminergic neurons in the substantia nigra a 
patient with PD theoretically could lead to 
hyperactivity of the caudate nucleus and the putamen. 
It may be accompanied by the permanent presence of 
excitatory signals to the corticospinal motor control 
system. Excessive excitation of many or all muscles 
of the body leads to development of their rigidity. 
After the loss of inhibition in the feedback path, the 
excitement in some of this path might easily oscillate 
leading to tremor characteristic of PD.  
More than 50-60% of dopaminergic nigrostriatal 
neurocytes die before clinical implications of PD 
(bradykinesia, increased muscle tone, resting tremor) 
begins. There is an assumption of the existence of 
multiple mechanisms by which brain cells may die 
[2]. One of the mechanisms is the pathological 
accumulation of the protein alpha-synuclein that is 
associated with ubiquitin in the damaged cells. This 
insoluble protein accumulates intracellular in neurons 
forming inclusions called Lewy bodies. Lewy bodies 
initial manifest in the olfactory bulb, medulla 
oblongata and the tegmentum of pons, and at this 
stage the disease is asymptomatic. During 
progression of the disease, Lewy bodies manifest in 
the substantia nigra, areas of the mesencephalon and 
basal forebrain, and in the last stage in the neocortex. 
These areas of the brain represent the main sites of 
the neurons degeneration in PD; however, Lewy 
bodies may not cause cell death, they can also carry a 
protective function. Other mechanisms of cell death 
include proteasome and lysosomal systems 
dysfunction and reduced mitochondrial activity. The 
accumulation of iron in the substantia nigra is usually 
registered in combination with protein inclusion. It 
may be associated with oxidative stress, protein 
aggregation and neuron death, but these mechanisms 
are understudied.  The majority of patients have 
cognitive defects, affective disorders and autonomic 
disturbances, which can relate to the damage of the 
structures other than the nigrostriatal pathway.  
Neurophysiologically patients with PD have an 
increase in the activity of neurons of the globus pallidus 
internus, which send excitation pulse to the Luys body 
as a result of loss inhibitory dopaminergic effects on 
neostriatum. The increase of the deceleration pulse from 
the globus pallidus internus (and, possibly, the pars 
reticulate of the substantia nigra) to nucleus ventralis 
anterior and ventral intermediate nucleus of thalamus 
leads to a decrease in the activation, patients find it 
difficult to start movement, because they have violation 
of activation of the supplementary motor area, while 
explaining the rigidity and tremor more difficult. In the 
early disease the condition of patients may improve on 
the top of administered therapy by the antiparkinsonian 
drugs.  
Despite extensive studies, the cellular mechanisms 
underlying the degeneration of dopaminergic neurons 
of the mesencephalon in PD are understudied. Studies 
on genetic and toxic animal models suggest the 
possibility that oxidative stress, mitochondrial 
dysfunction, aberrant processing of proteins by the 
ubiquitin-proteosome proteolytic system, inflammation 
and activation of apoptosis play a role in the death of 
dopaminergic cells [10, 11].  
Simplified model of the basal ganglia motor 
system provides an understanding of how indirectly 
degeneration of dopaminergic neurons of the substantia 
nigra is compensated by modulating synaptic 
transmission at other synapses within the basal ganglia, 
can provide opportunities for non-dopaminergic 
therapeutic strategies. The striatum is the primary input 
to the basal ganglia. It receives excitation from multiple 
areas of the cerebral cortex, including primary motor 
cortex and other motor areas.  
TEST MODEL OF THE PARKINSON'S 
SYNDROME 
A problem for experimental studies of the 
pathogenesis of PD is the inability of biological 
sampling from patients with this disorder, so there is 
practically no possibility of observing processes in 
living human cells in PD. There are well-known 
model of Parkinson's disease in vivo (in living 
organisms) and in vitro ("in vitro"). Closest to the 
processes of human cells are models of pathology in 
vivo on animals, but when they are used there are 
difficulties with results reproducibility, difficulty of 
the content of pure lines of animals and justify the 
use of models in vivo before the Ethics Committee.  
At the same time, in recent years use the models in 
vitro are increasing. Thus, cell culture is a universal 
method for the study "physiological" and pathological 
processes elucidate of the signal transfer mechanism, 
gene regulation, cell proliferation and the mechanisms 
of their death. These models do not rule out in vivo 
models, but it is a good supplement to them, allowing 
you to study the physiological processes and 
mechanisms of pathogenesis of diseases, to understand 
the signal transfer mechanism, gene regulation, cell 
proliferation and death.  
It is not revealed to PD occurred naturally in other 
animal species than humans, although animal models 
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which show some manifestations of the disease are used 
in research. There are genetic models that are based on 
unique gene mutations observed in nepotism PD. 
However, they are not able to recapitulate aspects of 
human disease, such as degeneration of dopaminergic 
neurons, and appeared to be more useful for the study 
of heredity of PD and not for the evaluation of new 
therapeutic strategies [12]. Animal models of PD are a 
means of assessing the ability of new drugs to reduce or 
stop the motor symptoms and to slow progression of 
neurodegeneration associated with this condition. 
Evaluation of new therapeutic target for the 
symptomatic treatment of PD often depends on the 
pharmacological and toxic models of PD in mice, rats 
and primates that are best suited to recreate the motor 
symptoms of the disease [13]. Pharmacological models 
are used to explore the therapeutic potential of the 
compounds, oriented on glutamate receptors, as they are 
convenient and economical. Pharmacological agents 
that induce the symptoms of PD include neuroplegics 
such as the mixed D1\D2 dopamine receptor antagonist 
haloperidol, which causes muscular rigidity, akinesia 
and catalepsy. One more thing is reserpine, which 
causes profound akinesia in rodents [13]. Since there is 
a lack of standardization of these models by different 
researchers, it is possible that this pharmacological 
model will produce different results due to different 
methodologies. Therefore it is very important to give 
attention to the methods for the interpretation and 
comparison of the results of these models. In addition, it 
is important to keep in mind that parkinsonism which is 
induced by pharmacological agents in rodents are 
reversible and do not reproduce the morphological 
markers of disease, and therefore cannot simulate all 
aspects of the disease caused by the degeneration of 
dopaminergic neurons of the substantia nigra. Toxic 
models of PD are useful for studying therapeutic 
strategies to treat motor symptoms and neuroprotection 
and to study the mechanisms of the disease. The 
appearance of Parkinson's disease symptoms in a group 
of drug addicts in the 1980-ies who consumed a 
contaminated consignment of the synthetic opiate 
MPTP (dopaminergic neurotoxin 1-methyl-4-phenyl-
tetrahydropyridine), led to the fact that MPTP was 
perceived as the agent that causes a parkinson's 
syndrome in primates, mice, and humans. MPTP is 
used to study the cellular mechanisms underlying the 
cell death of dopaminergic system. MPTP can be 
administrated systematically, but it needs to be 
converted in the brain into an active metabolite 1-
Methyl-4-phenylpyridinium ion (MPP+) by 
monoamine oxidase. MPP+ is selectively transported 
into dopaminergic nerve termination with help from the 
dopamine transporter and causing neurodegeneration by 
disrupting of mitochondrial function. In primates, 
MPTP administration closely replicates the behavioral 
problems of PD, and it is considered the best model for 
studying the antiparkinsonian effectiveness of new 
drugs for the treatment of humans. Other models on the 
basis of toxins include the insecticide rotenone, the 
herbicide paraquat and the fungicide maneb. Models 
based on toxins are most commonly used on primates. 
Transgenic rodent models that replicate various aspects 
of PD have also been studied [16]. The use of the 
neurotoxin 6-hydroxydopamine (6-OHDA) produces a 
model of Parkinson's disease in rats by targeting and 
destroying dopaminergic neurons in the nigrostriatal 
pathway with administration in the substantia nigra. 6-
OHDA causes unilateral lesion of motor behavior of 
rats, and new therapeutic agents can be evaluated for 
treatment of these effects. Despite the fact that is no 
animal model is not able to perfectly replicate human 
disease, these models can be tools to assess the 
therapeutic potential of new targets and agents.  
PRINCIPLES OF THERAPY 
OF PARKINSON'S DISEASE 
Despite the stage of the disease, the modern 
approach to the treatment of PD involves two main 
strategies such as the search for agents that can slow, 
delay or stop its progression (called neuroprotection) 
and the creation of new, more effective drugs for 
symptomatic treatment. The latter at the present time 
is recognized the primary. Principles of drug therapy 
of Parkinson's disease largely base on the concept of 
dopaminergic deficit, and also on modern concepts 
about the functioning of the dopaminergic synapse 
and the pathogenesis of neurodegenerative diseases. 
In accordance with these principles therapy of PD 
involves the use of drugs that increase the synthesis 
of dopamine in the brain; stimulate the release of 
dopamine from presynaptic terminals and inhibit its 
reuptake of presynaptic elements; inhibit the 
degradation (catabolism) of dopamine; stimulate the 
postsynaptic dopamine receptors; prevent of 
progressive neuronal death and slow the progression 
of the disease. The complex treatment of Parkinson's 
disease should include antioxidants (for example, 
natural vitamin E, not synthetic), exercise therapy. 
Because the disease is understudied, scientists still 
carry on polemics about possibility to slow the 
inevitable progression of the disease upon the 
existence of symptoms of PD.  
Levodopa (precursor of dopamine) is a 
stereoisomer of dihydroxyphenylalanine (DOPA), 
which, as opposed to the dopamine, penetrates well 
into CNS. Under the action of the enzyme DOPA-
decarboxylase levodopa is transformed into 
dopamine, thereby increasing its level in neostriatum. 
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The symptoms of Parkinson's disease disappear 
within a short period of time. Levodopa is effective 
only constant concentration control in the body. With 
disease progression, and a decrease in the number of 
cells of the neurons of the substantia nigra, its 
effectiveness is sharply reduced. 97-99% levodopa 
transforms into dopamine in peripheral tissues, 
causing many side effects of the drug. With the aim 
of reducing its number, levodopa is used in 
combination with inhibitors of DOPA decarboxylase 
(carbidopa, benserazide) that doesn’t pass through 
the CNS. This combination metabolism of levodopa 
can occur only in the brain. The use of combinations 
of levodopa and carbidopa ("Nakom", "Sinemet") 
increases the likelihood of side effects from the CNS, 
such as dyskinesia (80% of cases), anxiety, 
depression, delusions, hallucinations.  
MAO inhibitors (Selegiline, Rasagiline) 
metabolize dopamine, increasing its level in 
neostriatum. The use of these drugs with levodopa 
can reduce the dose of the latter. 
Tolcapone, entacapone are COMT inhibitors, an 
enzyme that is responsible for the distribution of 
dopamine in the neurons. The administration of the 
combined precursor of dopamine leads to 
compensatory activation of this enzyme. The 
treatment efficiency is lowered. Tolcapone and 
entacapone inhibit COMT, allowing reducing the 
dose of levodopa. 
Dopamine receptor agonists are bromocriptine 
(partial agonist of the dopamine receptors (D2)), 
lisuride (a derivative of ergot alkaloids), pergolide 
(dopamine receptors agonist (D1 and D2)).  
Drug that inhibits excitation of neostriatum 
neurons by acetylcholine is trihexyphenidyl 
(Cyclodol) which is a muscarinic antagonist. Its 
effectiveness in PD is weaker than levodopa. It well 
eliminates tremor and muscular rigidity, but does not 
affect bradykinesia. It is used in composition of 
complex therapy. 
Glutamate receptors antagonists (NMDA) are a 
relatively new group of drugs. Glutamate is 
exitotoxic transmitter in relation to pathways. Its 
action on NMDA receptors induces the movement of 
Ca
2+
 inside the cell, which leads to a sharp increase 
of stimulation and subsequent neuronal death in PD. 
Drugs that block glutamate receptors (amantadine, 
symmetrel) reduce toxic effects caused by 
stimulation of NMDA receptors.  
Operative treatment of PD, which is aimed at 
reducing the activity of the Luys body, and deep 
brain stimulation, has been very effective [14, 15]. 
Deep brain stimulation (Luys body or the globus 
pallidus internus) significantly reduces motor 
symptoms (tremor, bradykinesia, rigidity), however, 
the exact mechanism by which this effect is achieved 
remains unclear. Unfortunately, surgery cannot be 
called widely available due to their relatively high 
cost and a large number of contraindications for their 
conduct. The fact that the lesion of the Luys body 
and globus pallidus with deep brain stimulation 
improves the symptoms of Parkinson's disease, 
suggests that pharmacological drugs which are able 
to reduce the activity of the Luys body can provide 
significant relief of motor symptoms.  
OVERVIEW OF TESTS OF DIFFERENT 
TYPES OF GLUTAMATE RECEPTORS 
ANTAGONISTS 
In the last 20 years there have been many studies 
showing that glutamate receptors antagonists can be 
used as drugs for the treatment of Parkinson's disease, 
as in combinations with levodopa and independently. 
The following is the main conclusions and assumptions 
obtained during the testing of these drugs.  
On the basis of numerous studies it can be 
assumed antiparkinsonian effect of NMDA receptors 
antagonists, since NMDA receptors mediate 
glutamatergic excitation of neurons in the striatum 
and Luys body, which is shown in various animal 
models (rats treated with haloperidol, monkeys 
treated with MPTP) [7]. Receptor blockade may be 
competitive and noncompetitive antagonists. 
Competitive antagonists of NMDA receptors (SDZ 
220-581) directly block glutamate recognition site of 
the NMDA-receptor. Noncompetitive antagonists of 
NMDA receptors (MK-801, dextrorphan, MSZ 
2\579, CP-101606) connect the phencyclidine 
recognition site of the NMDA receptors. It is known 
that these antagonists and antagonists of the glycine 
site (MRZ 2\570, L-701324, (R)-HA-966)) revert 
catalepsy and muscular rigidity which are induced by 
blockade of dopamine receptors in rats. Numerous 
studies show that NMDA receptors antagonists such 
as MK-801 and MRZ 2\579, also revert akinesia and 
other motor disorders in rodents, whereas antagonists 
of the glycine site of the NMDA-receptors is not 
effective in this model. Assume that the 
antiparkinsonian effect of NMDA receptors 
antagonists consist in blockade of the activity of 
these receptors in the striatum and the output nuclei 
of the basal ganglia. Another possible mechanism by 
which this effect is achieved is the reduction in the 
release of acetylcholine from cholinergic neurons of 
the striatum. It is also interesting that some NMDA 
receptors antagonists can potentiate the effect of 
levodopa suppressing motor fluctuations and 
dyskinesia that was shown in models of rodents and 
primates, and consequently it can be most effective in 
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combination with levodopa therapy. There is a 
perception that global inhibition of NMDA receptors 
may lead to the development of serious side effects, 
such as psychosis, learning disability and disordered 
motor function. This assumption leaves in doubt the 
development prospect of NMDA receptors as new 
therapeutic target. Therefore testing of combinations 
of NMDA receptor specific subunits has renewed 
interest in this issue. NR2B is a subunit of NMDA 
receptor in a large number is found in the striatum 
and in nuclei of the basal ganglia, so it is assumed 
that agents that selectively affect NMDA receptors 
containing the NR2B subunit may have more specific 
impact on the function of the receptor in areas of the 
brain relevant to the pathophysiology of PD. Such 
agents have been developed and studied their 
antiparkinsonian effects in animal models. For 
example, traksoprodil (CP-101606) changes 
catalepsy caused by haloperidol in rats and reducing 
motor symptoms of Parkinson's disease in affected by 
MPTP monkeys. Another NMDA NR2B selective 
receptor antagonist ifenprodil also reduces motor 
symptoms of PD in affected by MPTP monkeys. In 
addition, these drugs improve the effectiveness of 
levodopa that speaks about the clinical benefits of 
combination treatment. 
At present amantadine is only used as the 
NMDA receptors antagonist, which blocks the 
noncompetitive NMDA-receptors in therapeutically 
effective concentrations. Amantadine stimulates 
release of dopamine from presynaptic terminals, 
reduces the reuptake dopamine in the synapse, 
inhibits glutamatergic influence the frontal cortex on 
the striatum and has a distinct holinoblokirutm 
anticholinergic activity. As antagonist of glutamate 
receptors amantadine can implement its action at the 
level of the excitotoxic cascade [16, 17]. 
Although clinical benefit of amantadine 
monotherapy is questionable, double-blind, placebo-
controlled study showed that amantadine reduces 
dyskinesia and motor fluctuations in patients treated by 
levodopa. These data suggest that further study NMDA 
receptors antagonists may be of utility to complex 
therapy with levodopa. Besides amantadine inhibits the 
development of dementia in patients with PD, 
suggesting another positive effect of the blockade of 
NMDA receptors. Another NMDA receptors antagonist 
remacemide was also studied in patients with PD, both 
as monotherapy and in complex with levodopa. 
However, despite its antiparkinsonian effect in rats and 
primates, it has not shown the desired effect on people, 
causing some doubts in the use of NMDA receptors 
antagonists in the symptomatic treatment of PD. Thus 
further clinical studies using more selective drugs are 
very promising [7]. 
AMPA receptors antagonists were also proposed 
as potential therapeutic agents; however, preclinical 
studies have shown that they do not possess 
antiparkinsonian activity in monotherapy. For 
example, systemic administration of NBQX and 
GYKI 52466 does not prevent catalepsy induced by 
haloperidol in rats. NBQX monotherapy has also not 
improved motor symptoms in rats induced by 6-
OHDA and MPTP affected primates. In addition 
GYKI 52466 has no effect on akinesia in rats with 
monamine deficite, and does not intensify activities 
of levodopa in the same model. However, other 
studies have shown antiparkinsonian effect of AMPA 
receptors antagonists, independently and in 
combination with dopaminergic therapy. For 
example, NBQX has set up muscular rigidity (but not 
akinesia) induced by reserpine in rats, and motor 
deficite in MPTP affected primates. Also noted that 
NBQX improves the ability of levodopa to set up 
motor deficite in lesions of the substantia nigra in rats 
and primates. It is assumed that the different results 
of the studies were due to the fact different methods 
of induction of parkinsonism in animals (models with 
the use of neurotoxins has been more promising). 
Preclinical studies of AMPA receptors 
antagonists in the treatment of levodopa-induced 
dyskinesias gave more encouraging results for the 
potential use of these drugs in the treatment of PD. 
Noncompetitive AMPA receptors antagonist 
LY300164 (Talampanel) improves motor symptoms 
and reduces levodopa-induced dyskinesia in MPTP 
affected monkeys. Competitive AMPA receptors 
antagonist – LY293558 in combination with 
levodopa reduces levodopa-induced dyskinesia in 6-
OHDA rats. Interestingly, combined blockade by low 
(ineffective) doses of the AMPA and NMDA 
receptors antagonists reduces levodopa-induced 
dyskinesia in rats and primates, suggesting the 
possibility of using low doses of glutamate receptors 
antagonists to reduce dyskinesia [7].  
Metabotropic glutamate receptors (mGluR), in 
contrast to the "fast" ionotropic, provide a slow 
response to glutamatergic signals, and also represent 
a therapeutic target for the treatment of PD. 
Metabotropic glutamate receptors consist of seven 
transmembrane domains connected to to G-proteins, 
which mediate most of the effects of these receptors 
activation. Itself receptors consist of two subunits one 
of which binds glutamate. Metabotropic glutamate 
receptors (mGluR) are divided into three groups 
(mGluRI , mGluRII and mGluRIII ), although 
discovered eight genes that encode it (mGluRI 
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includes mGluR1 and -5, mGluRII is mGluR2 and -3, 
mGluRIII is mGluR4, -6, -7). Metabotropic 
glutamate receptors are activated by lower 
concentrations of glutamate than the main ionotropic 
AMPA receptors. A group of mGluRI are usually 
located on the postsynaptic membrane around the 
synaptic cleft. The effect of activation of these 
receptors opposes the effect of dopamine and directly 
stimulates the hyperactive nuclei in the Parkinsonian 
brain [18]. Furthermore, its activation potentiates 
currents of NMDA receptors in the striatum and Luys 
body. Antagonists of these receptors could have 
antiparkinsonian effect by reducing the excitation of 
hyperactive basal ganglia. In accordance with this 
hypothesis, several negative allosteric modulators of 
mGluR5 (MPTP and МТЕР) have antiparkinsonian 
effect on animal models. Interestingly, combined 
treatment by МРЕР and A2A adenosine receptors 
antagonists causes a noticeable reduction of akinesia 
in 6-OHDA or reserpine affected rats. This suggests 
the effectiveness of symptomatic therapy of PD with 
the combination of mGluR5 antagonists and A2A 
adenosine receptors antagonists. A similar effect is 
observed with the introduction of МРЕР and MK-
801 in 6-OHDA affected rats, which also indicates a 
possible antiparkinsonian effectiveness of 
simultaneous administration of NMDA receptors 
antagonists and mGluR5 antagonists. Systemic 
administration of MTEP to 6-OHDA affected rats 
reduces levodopa-induced dyskinesias in animals for 
a long time treated with levodopa. These data 
indicate that the possibility of mGluR5 antagonists 
may be useful for symptomatic treatment of PD in 
patients receiving long-term treatment by levodopa. 
Despite the positive result in the study of 
antiparkinsonian effect of  mGluR5 antagonists, the 
mGluR1 antagonists (EMQMCM) failed to reduce 
levodopa-induced dyskinesia, in connection with 
which they cannot be a promising target for the 
treatment of motor symptoms of PD.  
The data of electrophysiological studies show 
that the activation of mGluRII in the hypothalamic-
nigral synapses reduces their excitation. In 
accordance with this intranigral or 
intracerebroventricular adminisrtation of the 
mGluRII antagonist (DCG-IV, LY379268) restores 
the reserpine-induced akinesia in rats. Another 
mGluRII antagonist (LY354740) reverses 
haloperidol-induced catalepsy and muscular rigidity 
in rats. However mGluRII do not affect the 
locomotor deficit caused by the reserpine to rats, 
which limits the therapeutic potential of this group to 
relief the motor symptoms of PD. Physiological 
studies on brain slice of rats showed that the selective 
mGluRIII agonist (L-AP4) reduces synaptic 
transmission striato-pallidal and the hypothalamic-
nigral synapses. Also microdialysis studies have 
shown that L-AP4 and L-SOP reduce the release of 
GABA in the globus pallidus in rats. These data 
suggest that activation of mGluRIII can facilitate 
motor symptoms of PD, or by reducing the activity of 
the indirect pathway, or by reducing the activity of 
the nuclei in the hypothalamus. L-AP4 may be very 
effective in the treatment of PD symptoms, because it 
acts on the asymmetry of the forelegs 6-OHDA 
affected rats to the same extent as levodopa. 
Intrapallidal administration of L-SOP facilitates the 
reserpine-induced akinesia in rats, which confirms 
the hypothesis that the decrease in the activity of 
these synapses can have therapeutic efficacy. 
Glutamate receptors may be promising targets 
for treatment of neurological and psychiatric 
complications associated with PD, such as anxiety, 
depression and cognitive defects. The mGluRII and 
mGluR5 antagonists have anxiolytic action in 
preclinical models of anxiety, suggesting the 
possibility of their use for the treatment of both 
motor and psychiatric symptoms of PD. Also 
mGluRIII, mGluR5 and mGluRII antagonists are 
effective in preclinical models of depression, 
suggesting that they may be targets for treatment of 
depression in patients with PD. 
CONCLUSION 
The main drugs in the treatment of PD are 
levodopa and its derivatives, as well as the 
phenothiazine type antipsychotics and anticholinergic 
drugs. Unfortunately, they have quite a large number 
of side effects, and over time, the dosage should be 
increased, otherwise its cease to be effective. This 
poses a lot of problems. The physician should 
determine the time of starting therapy and the group 
of drugs with which is more expedient to start the 
treatment to postpone the development of side effects 
at a later date. Until now, scientists and clinical 
physicians have failed to find ways of slowing down 
the pathological process, and the more it stops or 
prevent. Although PD is tried to cure, the experts can 
only partially eliminate the symptoms but not the 
cause itself. Today, all the efforts of scientists aim at 
finding drugs which are not only soften the 
symptoms of the disease, but also stop the 
degenerative processes responsible for its 
progression. 
The study of glutamate receptors antagonists is 
an important task in the search for new 
pharmacological agents for the treatment of PD. 
Selectiveness of new agents is a key feature. 
Although the development of selective agents will 
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help to understand which subtypes of receptors 
mediate pro – or antiparkinsonian effects, it remains 
possible that the ideal treatment for PD will be 
directed at several subtypes of receptors. 
ABBREVIATION LIST 
6-OHDA – 6-hydroxydopamine 
AMPA – alpha-amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate 
BBB – blood-brain barrier 
CNS- central nervous system 
COMT – catechol-O-methyltransferase 
DOPA – dihydroxyphenylalanine  
GABA – gamma-amino-butyric acid 
MAO-B – monoamine oxidase type B 
mGluR – Metabotropic glutamate receptors  





NMDA – N-methyl-D-aspartate 
PD – Parkinson's Disease 
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